EU/3/15/1489

About

On 21 May 2015, orphan designation (EU/3/15/1489) was granted by the European Commission to Toleranzia AB, Sweden, for fusion proteins composed by a genetically modified cholera toxin subunit A1, peptides from the acetylcholine receptor alpha chain and a dimer of the D fragment from Staphylococcus aureus protein A for the treatment of myasthenia gravis.

Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in April 2019 on request of the Sponsor.

Key facts

Active substance
Fusion proteins composed by a genetically modified cholera toxin subunit A1, peptides from the acetylcholine receptor alpha chain and a dimer of the D fragment from Staphylococcus aureus protein A
Disease / condition
Treatment of myasthenia gravis
Date of first decision
21/05/2015
Outcome
Withdrawn
EU designation number
EU/3/15/1489

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Toleranzia AB
Arvid Wallgrens backe 20, 8th floor
413 46 Goteborg
Sweden
Tel. +46 704 566 441
Fax +46 317 865 150
E-mail: martina.verolin@toleranzia.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating